Product Description
For Lumbosacral Radiculopathy
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sciatica|Radiculopathy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| P12-06 | P2 |
Completed |
Radiculopathy|Sciatica |
2015-10-01 |